Maaike Swets

111 IL-6 inhibitors in hospitalised COVID-19 patients 5 Group Estimate (95% CI) 8 mg/kg 1 Fixed dose tocilizumab 1.12 (0.97 to 1.30) Low dose tocilizumab 1.05 (0.90 to 1.22) Sarilumab 400mg 1.15 (1.01 to 1.32) Supplementary Table 1. Multivariable Cox proportional hazards regression analysis looking at 60-day mortality and correcting for age, sex, immunocompromised status and Charlson Comorbidity index, in which all patients with unknown outcome were assumed to have survived to the end of follow up Group Estimate (95% CI) 8 mg/kg 1 Fixed dose tocilizumab 1.42 (1.26 to 1.60) Low dose tocilizumab 1.33 (1.17 to 1.52) Sarilumab 400mg 1.38 (1.23 to 1.55) Supplementary Table 2. Multivariable Cox proportional hazards regression analysis looking at 60-day mortality and correcting for age, sex, immunocompromised status and Charlson Comorbidity index, in which all patients with unknown outcome were assumed to have died on the day of hospital discharge Supplementary Figure 3. Unadjusted Kaplan-Meier survival curve in ICU admitted patients

RkJQdWJsaXNoZXIy MTk4NDMw